Consistently, a bioinformatics analysis of pancreatic cancer-specific datasets from TCGA and the Cancer Therapeutics Response Portal (CTRP) identified CEACAM5 as a candidate stemness-related inhibitory ICP in pancreatic cancer. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.